We'd be surprised if Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) shareholders haven't noticed that the President, Fred Aslan, recently sold US$244k worth of stock at US$9.01 per share. On the bright side, that sale was only 1.7% of their holding, so we doubt it's very meaningful, on its own.

Artiva Biotherapeutics Insider Transactions Over The Last Year

Notably, that recent sale by Fred Aslan is the biggest insider sale of Artiva Biotherapeutics shares that we've seen in the last year. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$7.84. So it is hard to draw any strong conclusion from it.

Artiva Biotherapeutics insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Does Artiva Biotherapeutics Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Based on our data, Artiva Biotherapeutics insiders have about 0.7% of the stock, worth approximately US$2.9m. We prefer to see high levels of insider ownership.

So What Does This Data Suggest About Artiva Biotherapeutics Insiders?

Insiders haven't bought Artiva Biotherapeutics stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. When you consider that most companies have higher levels of insider ownership, we're a little wary. We'd certainly practice some caution before buying! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing.

But note: Artiva Biotherapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.